COMMUNIQUÉS West-GlobeNewswire

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/10/2026
BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on October 1, 2026, the Compensation [...]
Legacy Opens Acres Homes Clinic to Expand Access to Care in a Historic Houston Community
06/10/2026
New 26,200-square-foot clinic brings coordinated, affordable care under one roof for Acres Homes families Legacy Community Health, Houston Methodist, elected officials and community leaders celebrate the grand opening [...]
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
06/10/2026
WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate [...]
Baylor Genetics Selected as the Lead Sequencing Partner for Florida’s Sunshine Genetics Pilot Program Launch
05/10/2026
The company will provide comprehensive Whole Genome Sequencing for the initial launch of the first statewide genomic newborn screening program HOUSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Baylor Genetics, a leading [...]
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
05/10/2026
Company Announcement COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; October 5, 2026 EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and [...]
Cerene® Cryotherapy Brings Free Mother-Daughter Period Education Brunch to Indianapolis Area
05/10/2026
CARMEL, Ind., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Channel Medsystems’ Cerene® Cryotherapy is bringing its Cycles & Seasons Mother-Daughter Brunch to the Indianapolis area on Saturday, October 10, offering local [...]
FDA Clears Motivista (CT-155), the First Authorized Treatment for Negative Schizophrenia Symptoms
05/10/2026
NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Click Therapeutics, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance (marketing authorization) for Motivista, a prescription [...]
Major shareholder announcement - BlackRock, Inc.
05/10/2026
ANNOUNCEMENT NO. 318 5 October 2026 Pursuant to section 30 of the Danish Capital Markets Act, notice is hereby given that BlackRock, Inc. has notified ChemoMetec that, on 29 September 2026, BlackRock, Inc. increased its [...]
ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development
05/10/2026
ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable target Cancer Research UK to fully fund, sponsor, design, and execute CTA-enabling studies and Phase 1/2 [...]
iCell Gene Therapeutics Announces Upcoming Conference Presentations
05/10/2026
STONY BROOK, N.Y., Oct. 05, 2026 (GLOBE NEWSWIRE) -- iCell Gene Therapeutics ("iCell Gene"), a clinical-stage biopharmaceutical company developing autologous and in vivo CAR T cell therapies for autoimmune diseases and [...]
BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day
05/10/2026
- October 6 YouTube premiere featuring Sway Calloway, Howard “H” White and leading medical and cultural voices anchors community education nationwide PALO ALTO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma [...]
Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/10/2026
PHILADELPHIA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically [...]
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
05/10/2026
WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate [...]
Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting
05/10/2026
IRVINE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation will be featured at the upcoming American Society of Nephrology Kidney Week [...]
Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504
05/10/2026
On track to initiate dosing by early November 2026; topline Phase 1 proof-of-mechanism data anticipated approximately six months following study initiation Randomized, double-blind, placebo-controlled study will [...]
Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121
05/10/2026
Initiated a Phase 1/2 clinical trial to enroll healthy volunteers and patients with Urea Cycle Disorders of any mutational background Administered a single dose of 2mg/kg to the first cohort of healthy volunteers [...]
Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED
05/10/2026
BOSTON, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced it has entered into a definitive agreement to sell its Microfluidics business [...]
Inspire Medical Systems, Inc. to Report Third Quarter 2026 Financial Results on November 2, 2026
05/10/2026
MINNEAPOLIS, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the third quarter 2026 after the close of trading on Monday, November 2. Inspire’s [...]
Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team
05/10/2026
Strengthens leadership team with appointments of John Brottem as general counsel and Amelia Merrill as chief people officer FREMONT, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR) a [...]

Pages